1994 Fiscal Year Final Research Report Summary
Development of novel cardiotonic agents
| Project/Area Number |
04557009
|
|---|
| Research Category |
Grant-in-Aid for Developmental Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Yamagata University School of Medicine |
|---|
Principal Investigator |
ENDOH Masao Yamagata University School of Medicine, 医学部, 教授 (40004668)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Keywords | OPC-18790 / OPC-8212 / positive inotropic effect / cyclic AMP / Ca^<2+> sensitizers / intracelluar Ca^<2+> / Org 9731 / mechanism of action of cardiotonics |
|---|
| Research Abstract |
The purpose of the study was to elucidate the mechanism of action of novel cardiotonic agents to provide basic information about useful for clinical application of these agents. Among new compounds investigated, Org 30029 [N-hydroxy-5,6-dimethoxybenzo [b] thiophene-2-carboximide hydrochloride] was the agent with most efficacious positive inotropic effect (PIE), which was mainly due to an increase in Ca^<2+> sensitivity of myofibrils. Because agents belonging to this class (Ca^<2+> sensitizer) neither require activation energy nor cause Ca^<2+> overload, they may provide beneficial clinical procedures to cure the patients with heart failure. Org 3731 with a slight modification of chemical structure of Org 30029 had much less Ca^<2+> sensitizing action and acted mainly by PDE inhibition, indicating that the site of these actions may possess a closely related characteristic. Another result obtained are concerned with the mechanism of action of PDE III inhibitors in intact cardiac muscle.
… More
These are summarized as follows : 1) PDE isozymes involved in cAMP hydrolysis in mammalian cardiac muscle show a wide range of species dependent variation ; 2) PDE inhibitors have a dual action, i.e., a direct PIE and the action to potentiate the PIE of adrenoceptor activation. The former action requires much higher concentration than the latter, which has a crucial meaning in clinical application of these agents ; 3) some novel compounds such as vesnarinone and pimobendan possess ancillary actions in addition to PDE inhibition. Since both agents have beneficial effects on the prognosis (survival rate) of the patients with severe heart failure, it is important to differentiate which mechanisms contribute most significantly to the clinical usefulness ; 4) while cAMP decreases the Ca^<2+> sensitivity of myofibrils in association with phosphorylation of troponin I,PDE III inhibitors did not produce such an action in contrast to beta- agonists, implying the intracellular compartmentation of cAMP in myocardial cells. Pathophysiological relevance of this difference under clinical setting is unknown for the time being and requires further study. Several novel agents have been developed, but there are no agents so far to replace digitalis in the treatment of heart failure. Further intensive effort will be required including evaluation of the clinical usefulness of these agents by careful investigation and synthesis of new agents with novel mechanism. Less
|
-
-
-
-
-
-
-
-
-
-
[Publications] Endoh, M., Kawabata, Y., Katano, Y., Norota, I.: "Effects of a novel cardiotonic agent((<minus-plus>))-6-[3-(3,4-dimethoxybenzylamino)-2-hydroxypropoxy]-2(1H)-quinolinone (OPC-18790) on contractile force, cyclic AMP level, and aequorin light transients in dog ventricular myocardiu " Journal of Cardiovascular Pharmacology. 23. 723-730 (1994)
Description
「研究成果報告書概要(欧文)」より
